Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Videos

Pathways Disruptors in Ovarian Cancer

Pathways Disruptors, a series hosted by Journal of Clinical Pathways, reviews key findings and takeaways of the latest research in oncology, focusing on the potential impact of new data on current pathway programs. 

Winston Wong, PharmD, Editor-in-Chief of the Journal of Clinical Pathways, discusses the final read-out of the ATHENA-MONO trial, an international, randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib as first-line maintenance treatment across a diverse patient population with newly diagnosed ovarian cancer. 

 

 

Advertisement

Advertisement

Advertisement